212 related articles for article (PubMed ID: 15907782)
1. Mechanism of action of ferrocene derivatives on the catalytic activity of topoisomerase IIalpha and beta--distinct mode of action of two derivatives.
Sai Krishna AD; Panda G; Kondapi AK
Arch Biochem Biophys; 2005 Jun; 438(2):206-16. PubMed ID: 15907782
[TBL] [Abstract][Full Text] [Related]
2. A study of the topoisomerase II activity in HIV-1 replication using the ferrocene derivatives as probes.
Kondapi AK; Satyanarayana N; Saikrishna AD
Arch Biochem Biophys; 2006 Jun; 450(2):123-32. PubMed ID: 16712776
[TBL] [Abstract][Full Text] [Related]
3. A three-dimensional quantitative structure-activity analysis of a new class of bisphenol topoisomerase IIalpha inhibitors.
Liang H; Wu X; Yalowich JC; Hasinoff BB
Mol Pharmacol; 2008 Mar; 73(3):686-96. PubMed ID: 18045852
[TBL] [Abstract][Full Text] [Related]
4. A three-dimensional quantitative structure-activity relationship study of the inhibition of the ATPase activity and the strand passing catalytic activity of topoisomerase IIalpha by substituted purine analogs.
Jensen LH; Liang H; Shoemaker R; Grauslund M; Sehested M; Hasinoff BB
Mol Pharmacol; 2006 Nov; 70(5):1503-13. PubMed ID: 16880287
[TBL] [Abstract][Full Text] [Related]
5. C-terminal regions of topoisomerase IIalpha and IIbeta determine isoform-specific functioning of the enzymes in vivo.
Linka RM; Porter AC; Volkov A; Mielke C; Boege F; Christensen MO
Nucleic Acids Res; 2007; 35(11):3810-22. PubMed ID: 17526531
[TBL] [Abstract][Full Text] [Related]
6. Topoisomerase II poisoning and antineoplastic action by DNA-nonbinding diacetyl and dicarboxaldoxime derivatives of ferrocene.
Vashisht Gopal YN; Jayaraju D; Kondapi AK
Arch Biochem Biophys; 2000 Apr; 376(1):229-35. PubMed ID: 10729210
[TBL] [Abstract][Full Text] [Related]
7. A biochemical analysis of topoisomerase II alpha and beta kinase activity found in HIV-1 infected cells and virus.
Kondapi AK; Padmaja G; Satyanarayana N; Mukhopadyaya R; Reitz MS
Arch Biochem Biophys; 2005 Sep; 441(1):41-55. PubMed ID: 16091284
[TBL] [Abstract][Full Text] [Related]
8. Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.
Errington F; Willmore E; Leontiou C; Tilby MJ; Austin CA
Cancer Chemother Pharmacol; 2004 Feb; 53(2):155-62. PubMed ID: 14504921
[TBL] [Abstract][Full Text] [Related]
9. Salvicine functions as novel topoisomerase II poison by binding to ATP pocket.
Hu CX; Zuo ZL; Xiong B; Ma JG; Geng MY; Lin LP; Jiang HL; Ding J
Mol Pharmacol; 2006 Nov; 70(5):1593-601. PubMed ID: 16914642
[TBL] [Abstract][Full Text] [Related]
10. Substituted purine analogues define a novel structural class of catalytic topoisomerase II inhibitors.
Jensen LH; Thougaard AV; Grauslund M; Søkilde B; Carstensen EV; Dvinge HK; Scudiero DA; Jensen PB; Shoemaker RH; Sehested M
Cancer Res; 2005 Aug; 65(16):7470-7. PubMed ID: 16103101
[TBL] [Abstract][Full Text] [Related]
11. A series of alpha-heterocyclic carboxaldehyde thiosemicarbazones inhibit topoisomerase IIalpha catalytic activity.
Huang H; Chen Q; Ku X; Meng L; Lin L; Wang X; Zhu C; Wang Y; Chen Z; Li M; Jiang H; Chen K; Ding J; Liu H
J Med Chem; 2010 Apr; 53(8):3048-64. PubMed ID: 20353152
[TBL] [Abstract][Full Text] [Related]
12. Self-association and DNA binding properties of the human topoisomerase IIA alpha2HTH module.
Morant-Lhomel A; René B; Zargarian L; Troalen F; Mauffret O; Fermandjian S
Biochimie; 2006; 88(3-4):253-63. PubMed ID: 16213649
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of topoisomerase II catalytic activity by two ruthenium compounds: a ligand-dependent mode of action.
Gopal YN; Jayaraju D; Kondapi AK
Biochemistry; 1999 Apr; 38(14):4382-8. PubMed ID: 10194357
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the action of the topoisomerase II poison amsacrine by simple aniline derivatives: evidence for drug-protein interactions.
Finlay GJ; Atwell GJ; Baguley BC
Oncol Res; 1999; 11(6):249-54. PubMed ID: 10691026
[TBL] [Abstract][Full Text] [Related]
15. Topoisomerase II is a cellular target for antiproliferative cobalt salicylaldoxime complex.
Jayaraju D; Gopal YN; Kondapi AK
Arch Biochem Biophys; 1999 Sep; 369(1):68-77. PubMed ID: 10462441
[TBL] [Abstract][Full Text] [Related]
16. Characterization of DNA topoisomerase II alpha/beta heterodimers in HeLa cells.
Gromova I; Biersack H; Jensen S; Nielsen OF; Westergaard O; Andersen AH
Biochemistry; 1998 Nov; 37(47):16645-52. PubMed ID: 9843432
[TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of a novel series of pyranonaphthoquinones as topoisomerase II catalytic inhibitors.
Jiménez-Alonso S; Orellana HC; Estévez-Braun A; Ravelo AG; Pérez-Sacau E; Machín F
J Med Chem; 2008 Nov; 51(21):6761-72. PubMed ID: 18816045
[TBL] [Abstract][Full Text] [Related]
18. The QTK loop is essential for the communication between the N-terminal atpase domain and the central cleavage--ligation region in human topoisomerase IIalpha.
Bendsen S; Oestergaard VH; Skouboe C; Brinch M; Knudsen BR; Andersen AH
Biochemistry; 2009 Jul; 48(27):6508-15. PubMed ID: 19485418
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic mechanism of XK469: resistance of topoisomerase IIbeta knockout cells and inhibition of topoisomerase I.
Snapka RM; Gao H; Grabowski DR; Brill D; Chan KK; Li L; Li GC; Ganapathi R
Biochem Biophys Res Commun; 2001 Feb; 280(4):1155-60. PubMed ID: 11162648
[TBL] [Abstract][Full Text] [Related]
20. Synergistic interaction between histone deacetylase and topoisomerase II inhibitors is mediated through topoisomerase IIbeta.
Marchion DC; Bicaku E; Turner JG; Daud AI; Sullivan DM; Munster PN
Clin Cancer Res; 2005 Dec; 11(23):8467-75. PubMed ID: 16322310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
